Antagonist functional selectivity: 5-HT 2A serotonin receptor antagonists differentially regulate 5-HT 2A receptor protein level in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 1, 2011, Pages 99-105

  Yadav, Prem N ^a   Kroeze, Wesley K ^a   Farrell, Martilias S ^a   Roth, Bryan L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTANSERIN; CLOZAPINE; EPLIVANSERIN; GLEMANSERIN; HALOPERIDOL; KETANSERIN; M 11939; OLANZAPINE; PIMAVANSERIN; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG; VOLINANSERIN;

ANIMAL EXPERIMENT; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DOWN REGULATION; DRUG SELECTIVITY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BEHAVIOR, ANIMAL; BENZODIAZEPINES; BLOTTING, WESTERN; CLOZAPINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; PHENCYCLIDINE; RADIOLIGAND ASSAY; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS; SEROTONIN UPTAKE INHIBITORS; STEREOTYPED BEHAVIOR; UP-REGULATION;

EID: 80053146959     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.183780     Document Type: Article

References (39)

1. Abbas AI, Yadav PN, Yao WD, Arbuckle MI, Grant SG, Caron MG, and Roth BL (2009) PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. J Neurosci 29:7124-7136.
2. Allen JA and Roth BL (2011) Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 51:117-144.
3. Andree TH, Mikuni M, Tong CY, Koenig JI, and Meltzer HY (1986) Differential effect of subchronic treatment with various neuroleptic agents on serotonin2 receptors in rat cerebral cortex. J Neurochem 46:191-197. (Pubitemid 16185444)
4. Bergstrom DA and Kellar KJ (1979) Adrenergic and serotonergic receptor binding in rat brain after chronic desmethylimipramine treatment. J Pharmacol Exp Ther 209:256-261. (Pubitemid 9193696)
5. 2A receptor occurs via the endosome pathway in vitro. Mol Pharmacol 50:306-313.
6. 2A receptors during endocytosis. J Biol Chem 276:8269-8277.
7. Blackshear MA and Sanders-Bush E (1982) Serotonin receptor sensitivity after acute and chronic treatment with mianserin. J Pharmacol Exp Ther 221:303-308. (Pubitemid 12122941)
8. Brunello N, Chuang DM, and Costa E (1982) Different synaptic location of mianserin and imipramine binding sites. Science 215:1112-1115. (Pubitemid 12114093)
9. Costa T and Herz A (1989) Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 86:7321-7325. (Pubitemid 19254452)
10. Costall B and Naylor RJ (1995) Behavioural interactions between 5-hydroxytryptophan, neuroleptic agents and 5-HT receptor antagonists in modifying rodent responding to aversive situations. Br J Pharmacol 116:2989-2999.
11. Elphick GF, Querbes W, Jordan JA, Gee GV, Eash S, Manley K, Dugan A, Stanifer M, Bhatnagar A, Kroeze WK, et al. (2004) The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 306:1380-1383. (Pubitemid 39532516)
12. Galandrin S, Oligny-Longpré G, and Bouvier M (2007) The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci 28:423-430. (Pubitemid 47087968)
13. 2Areceptors by agonists and antagonists. Brain Res Bull 56:441-451.
14. 2A receptor. J Pharmacol Exp Ther 300:468-477.
15. Harvey JA, Quinn JL, Liu R, Aloyo VJ, and Romano AG (2004) Selective remodeling of rabbit frontal cortex: relationship between 5-HT2A receptor density and associative learning. Psychopharmacology (Berl) 172:435-442. (Pubitemid 38650980)
16. Horiguchi M, Huang M, and Meltzer HY (2011) The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther 338:605-614.
17. Leysen JE, Van Gompel P, Gommeren W, Woestenborghs R, and Janssen PA (1986) Down regulation of serotonin-S2 receptor sites in rat brain by chronic treatment with the serotonin-S2 antagonists: ritanserin and setoperone. Psychopharmacology (Berl) 88:434-444. (Pubitemid 16109552)
18. Magalhaes AC, Holmes KD, Dale LB, Comps-Agrar L, Lee D, Yadav PN, Drysdale L, Poulter MO, Roth BL, Pin JP, et al. (2010) CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling. Nat Neurosci 13:622-629.
19. Martin P, Waters N, Waters S, Carlsson A, and Carlsson ML (1997) MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride. Eur J Pharmacol 335:107-116. (Pubitemid 27450474)
20. Meltzer HY, Arvanitis L, Bauer D, Rein W, and Meta-Trial Study Group (2004) Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 161:975-984. (Pubitemid 38735983)
21. Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, and Friedman JH (2010) Pimavanserin, a serotonin2A receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacology 35:881-892.
22. O'Connor KA and Roth BL (2005) Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat Rev Drug Discov 4:1005-1014.
23. 2 receptor antagonism on the behavioral activation and immediate early gene expression induced by dizocilpine. J Pharmacol Exp Ther 287:839-846.
24. Peroutka SJ and Snyder SH (1980) Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science 210:88-90. (Pubitemid 11192054)
25. 2 receptors in mouse brain. Mol Pharmacol 43:84-89.
26. 2-adrenergic receptor function. Science 318:1266-1273.
27. 2 adrenoceptor complex. Nature 469:236-240.
28. Roth BL and Ciaranello RD (1991) Chronic mianserin treatment decreases 5-HT2 receptor binding without altering 5-HT2 receptor mRNA levels. Eur J Pharmacol 207:169-172.
29. Roth BL and Chuang DM (1987) Multiple mechanisms of serotonergic signal transduction. Life Sci 41:1051-1064. (Pubitemid 17125222)
30. Roth BL, Sheffler DJ, and Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353-359. (Pubitemid 38499762)
31. Stephenson RP (1956) A modification of receptor theory. Br J Pharmacol Chemother 11:379-393.
32. Stoessl AJ, Dourish CT, and Iversen SD (1990) Pharmacological characterization of the behavioural syndrome induced by the NK-3 tachykinin agonist senktide in rodents: evidence for mediation by endogenous 5-HT. Brain Res 517:111-116. (Pubitemid 20207227)
33. Urban JD, Clarke WP, Von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13. (Pubitemid 46025713)
34. 1-adrenergic receptor. Nature 469:241-244.
35. 2A receptor expression in the cerebral cortex studied using genetically modified mice. Front Neurosci 4:36.
36. 2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine2A receptors in vitro and in vivo. Neuroscience 91:599-606.
37. Willins DL, Alsayegh L, Berry SA, Backstrom JR, Sanders-Bush E, Friedman L, Khan N, and Roth BL (1998) Serotonergic antagonist effects on trafficking of serotonin 5-HT2A receptors in vitro and in vivo. Ann NY Acad Sci 861:121-127. (Pubitemid 29047708)
38. 2A serotonin receptors in cortical pyramidal neurons in vitro. Neuroscience 122:907-920.
39. Yadav PN, Abbas AI, Farrell MS, Setola V, Sciaky N, Huang XP, Kroeze WK, Crawford LK, Piel DA, Keiser MJ, et al. (2011) The presynaptic component of the serotonergic system is required for clozapine's efficacy. Neuropsychopharmacology 36:638-651.